Fzata, Inc.
Zhiyong Yang began their work experience in 2004 as a Postdoc at Massachusetts General Hospital. In 2007, they had a contract role at Amgen. From 2008 to 2012, they worked as a Research Scientist at EnVivo Pharmaceuticals. In 2012, they became a Faculty member at the University of Maryland and held this role until 2014. From 2014 to 2015, they were the CEO of ATA, LLC. Finally, since 2015, they have been the CEO of Fzata, Inc.
Zhiyong Yang has a PhD in Neuroscience from the University of Arizona. Following their doctoral studies, they pursued a PostDoc at the Mass General Institute of Neurodegenerative Diseases, Harvard Medical School, specializing in the field of Alzheimer’s Disease.
This person is not in any teams
This person is not in any offices
Fzata, Inc.
Fzata’s capturing the “holy grail” of oral biologics with our transformational Bioengineered Probiotic Yeast Medicines (BioPYM) modality. With $17M in non-dilutive NIH funding, Fzata has developed a pipeline of drug candidates for gastrointestinal-related disorders. BioPYM platform uses live yeast as a ‘factory’ to make recombinant therapeuticbiologics in the gut. Advantages over traditional biologics include: simple yeast manufacturing, no anti-drug antibody response, no toxicity, no refrigeration and no needles. BioPYM FZ002 first-in-human phase 1 clinical trial. for C. diff infection will be in 2023. Next is FZ006 for ulcerative colitis and Crohn's disease.